OPSENS ANNOUNCES CREDIT AGREEMENT WITH CIBC INNOVATION BANKING Quebec City, Quebec, February 27, 2019 – Opsens Inc. (“Opsens”) (TSX:OPS) (OTCQX:OPSSF) ) is pleased to announce that it has entered into an $8 M credit agreement (the “Agreement”) with CIBC Innovation Banking (CIBC). […]
Category: News & Events
ATTEND THE OPSENS SPONSORED LUNCH SYMPOSIUM AT CRT 2019
Attend the Opsens sponsored complimentary lunch educational symposium, “Coronary Physiology 2019: Covering All Your (Physiologic) Bases” at the CRT (Cardiovascular Research Technologies) 2019 Conference in Washington, DC. The OptoWire features a large nitinol core with excellent torque response and deliverability. With the […]
OPSENS – Q1 2019 REVENUES REACH A RECORD HIGH OF $9.1 M, A 43% INCREASE
Quebec City, Quebec, January 14, 2019 – Opsens Inc. (“Opsens” or the “Company”) (TSX:OPS) (OTCQX:OPSSF) today reported its results for the first quarter of 2019. Highlights Consolidated revenues totaled $9.1 M in the first quarter of 2019 compared with $6.4 […]
OPSENS’ dPR OBTAINS CE MARKING TO SELL IN EUROPE
Quebec City, Quebec, January 9, 2019 – Opsens Inc. (“Opsens” or the “Company”) (TSX:OPS) (OTCQX:OPSSF) has been granted CE marking for its diastolic pressure algorithm (“dPR”). Opsens’ dPR algorithm has been designed to assess intracoronary pressure with the heart at […]
OPSENS REPORTS Q4 and FY2018 RESULTS – RECORD ANNUAL REVENUE SURPASS $24 M AND RECORD QUARTERLY FFR REVENUES AT $4.1 M
Quebec City, Quebec, November 28, 2018 – Opsens Inc. (“Opsens” or the “Company”) (TSX:OPS) (OTCQX:OPSSF) today reported its results for the fourth quarter and fiscal year ended August 31, 2018. Highlights for the quarter and for the year Fractional Flow […]
OPSENS RECEIVES HEALTH CANADA APPROVAL FOR dPR INTENDED FOR THE DIAGNOSIS OF CORONARY STENOSIS WITH THE HEART AT REST
Quebec City, Quebec, November 27, 2018 – Opsens Inc. (“Opsens”) (TSX:OPS) (OTCQX:OPSSF) announced today that it has obtained approval from Health Canada to market its dPR Proprietary Resting Index, which measures intracoronary pressure and establishes a diagnosis with the heart at […]
OPSENS – FIRST USE OF dPR FOR THE DIAGNOSIS OF CORONARY STENOSIS WITH THE HEART AT REST
Quebec City, Quebec, November 8, 2018 – Opsens Inc. (“Opsens”) (TSX:OPS) (OTCQX:OPSSF) announces that its Diastolic Pressure Ratio called dPR, has been used for the first time by Dr. Hitoshi Matsuo, cardiologist and President of the Gifu Heart Center Japan. The measurement of Fractional […]
OPSENS – 50,000 PATIENTS DIAGNOSED WITH THE OPTOWIRE
Quebec City, Quebec, November 1st, 2018 – Opsens Inc. (“Opsens” or the “Company”) (TSX:OPS) (OTCQX:OPSSF) has reached an important milestone with more than 50,000 patients assessed with the OptoWire™, a pressure guidewire used to measure Fractional Flow Reserve (“FFR”) to […]
OPSENS TO HOST INVESTOR WEBINAR ON THURSDAY, OCTOBER 4 TO PROVIDE UPDATE ON RECENT DEVELOPMENTS
OPSENS TO HOST INVESTOR WEBINAR ON THURSDAY, OCTOBER 4 TO PROVIDE UPDATE ON RECENT DEVELOPMENTS Quebec City, Quebec, October 3, 2018 – Opsens Inc. (“Opsens” or the “Company”) (TSX:OPS) (OTCQX:OPSSF) will host an investor webinar and live Q&A session on […]
OPSENS – NEW PRODUCT FOR THE DIAGNOSIS OF CORONARY STENOSIS WITH THE HEART AT REST
Quebec City, Quebec, September 20, 2018 – Opsens Inc. (“Opsens” or the “Company”) (TSX:OPS) (OTCQX:OPSSF) announces it has developed a product that will allow the diagnosis of coronary heart blockages with the heart at rest. Filing for regulatory approvals has […]
